Astrazeneca (AZN) Long-Term Investments (2009 - 2026)

Astrazeneca (AZN) has reported Long-Term Investments for 18 consecutive years, with -$12.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments fell 71.43% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$12.0 million (down 71.43% YoY), while the FY2025 annual figure was $302.0 million, up 12.69% from the prior year.
• Long-Term Investments came in at -$12.0 million for Q1 2026 at Astrazeneca, down from $302.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.1 billion in Q4 2022, with the low at -$12.0 million in Q1 2026.
• Average Long-Term Investments over 5 years is $169.9 million, with a median of $72.0 million recorded in 2023.
• Across the five-year window, Long-Term Investments surged 2736.36% in 2024 and tumbled 187.5% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $1.1 billion in 2022, then plunged by 86.21% to $147.0 million in 2023, then surged by 82.31% to $268.0 million in 2024, then advanced by 12.69% to $302.0 million in 2025, then tumbled by 103.97% to -$12.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered -$12.0 million, $302.0 million, and $296.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.